Eaton's Battery Configuration Switch Provides EV Charging Flexibility
Intelligent power management company Eaton today announced it has partnered with Munich Electrification to develop and market its battery configuration switch (BCS), an advanced solution for 400-volt/800-volt dual string battery packs in electrified vehicles. This innovative, integrated, bi-stable device for parallel/series reconfiguration allows 800-volt vehicles to effectively charge via a 400-volt charger, while also offering numerous benefits compared to traditional solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003158793/en/
Eaton’s Battery Configuration Switch enables the reduction of up to 12 components in a battery disconnect unit, simplifying the system and streamlining packaging and assembly. (Photo: Business Wire)
“At Eaton, we're leveraging our extensive background in developing electrified mobility solutions to launch this promising new technology in partnership with Munich Electrification, which specializes in developing cutting-edge battery management systems,” said Mark Schneider, president, Eaton’s eMobility. “There are a lot of 800-volt vehicles in the market, but many charging stations can only supply 400-volt power. BCS provides charging flexibility to consumers who want access to an expanded network of DC chargers."
Designed for automotive, light commercial and UTV applications, Eaton’s BCS enables the reduction of up to 12 components in a battery disconnect unit, simplifying the system and streamlining packaging and assembly. Furthermore, the BCS minimizes contact resistance, enhancing overall system efficiency and performance by reducing the number of contact points required by conventional contactors.
Ensuring higher EV safety standards, the BCS has a mechanical interlock that prevents pack short circuits due to crashes, software bugs, or contactor malfunctions. The BCS can also maintain stable conditions when the electronic control unit loses power. Its bi-stable nature enhances efficiency during normal operations by eliminating the hold current of a traditional contactor, and also provides resilience against low voltage faults by maintaining a safe condition for a wide range of potential failure modes.
“We are thrilled to collaborate with Eaton in launching this groundbreaking new technology developed by our outstanding R&D team,” said Uwe Wiedeman, managing director, Munich Electrification. “Munich Electrification’s legacy of innovation in the EV battery industry combined with Eaton’s expertise in electrical switching and automotive manufacturing is helping us to solve our customers’ biggest challenges together.”
Learn about Eaton’s BCS technology and other vehicle electrification solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
About Munich Electrification
Munich Electrification is a leading provider of innovative battery management solutions that has the development of sustainable battery management systems and electronics in its DNA. Munich Electrification offers state-of-the-art methods in software and electronics development and has profound knowledge of passionate professionals from 24 nations who have already worked for well-known automotive manufacturers. With a commitment to innovation and a passion for pushing the boundaries of what is possible, Munich Electrification strives to be a distinctive lead supplier for the electrified automotive world and beyond.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003158793/en/
Contacts
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
For more information, please visit www.munichelectrification.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.munichelect
rification.com&esheet=54130942&newsitemid=20241003158793&lan=en-US&anchor=www.mu
nichelectrification.com&index=4&md5=c205f2cfe6de53f43fb1fc02079e5433 or contact:
Munich Electrification GmbH
Gesa Brahm | Brand Manager
Landaubogen 1 | 81373 Munich | Germany
P +49 89 890 83 515| g.brahm@munichelectrification.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom